Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor Beta - Drugs In Development, 2022, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 6 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Women's Health, Musculoskeletal Disorders, Genetic Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders and Respiratory which include indications Multiple Sclerosis, Alzheimer's Disease, Breast Cancer, Osteoporosis, Prostate Cancer, Vasomotor Symptoms of Menopause (Hot Flashes), Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Respiratory Distress Syndrome, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Dementia, Demyelinating Diseases, Depression, Endometrial Cancer, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Inflammation, Leiomyosarcoma, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic’s Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Precocious Puberty, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Furthermore, this report also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook